Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - A Europe against cancer program

Leukemia

Volumn 17, Issue 12, 2003, Pages 2474-2486

  Beillard, E ^a   Pallisgaard, N ^b   van der Velden, V H J ^c   Bi, W ^d   Dee, R ^e   van der Schoot, E ^e   Delabesse, E ^f   Macintyre, E ^f   Gottardi, E ^g   Saglio, G ^g   Watzinger, F ^h   Lion, T ^h   van Dongen, J J M ^c   Hokland, P ^b   Gabert, J ^a,i  

^a INSTITUT PAOLI CALMETTES   (France)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d APPLIED BIOSYSTEMS   (United States)

^e CENTRAL LABORATORY   (Netherlands)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g UNIVERSITY OF TURIN   (Italy)

^h ST ANNA CHILDREN S HOSPITAL   (Austria)

ⁱ HÔPITAL NORD   (France)

Author keywords

Control gene; Real time quantitative RT PCR; Residual disease; Sample quality; Standardization

Indexed keywords

ABELSON KINASE; BETA 2 MICROGLOBULIN; BETA GLUCURONIDASE; COMPLEMENTARY DNA; RNA;

ACUTE LEUKEMIA; ARTICLE; CALCULATION; CHRONIC LEUKEMIA; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; EUROPE; FUSION GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOGENE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; STANDARDIZATION;

EID: 9144271651     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403136     Document Type: Article

References (41)

1. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-554.
2. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T et al. BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: international standardization and clinical evaluation. Leukemia 2001; 15: 1185-1192.
3. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
4. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470.
5. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
6. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
7. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275-276.
8. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. GIMEMA-AIEOP Multi-center 'AIDA' Trial. Blood 1998; 92: 784-789.
9. Romana SP, Poirel H, Leconiat M, Flexor MA, Mauchauffe M, Jonveaux P et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86: 4263-4269.
10. Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998; 92: 574-588.
11. Grimwade D. Screening for core binding factor gene rearrangements in acute myeloid leukemia. Leukemia 2002; 16: 964-969.
12. Gabert J. Detection of recurrent translocations using real time PCR; assessment of the technique for diagnosis and detection of minimal residual disease. Haematologica 1999; 84: 107-109.
13. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-193.
14. Lion T. Current recommendations for positive controls in RT-PCR assays. Leukemia 2001; 15: 1033-1037.
15. Zhang Z, Harrison P, Gerstein M. Identification and analysis of over 2000 ribosomal protein pseudogenes in the human genome. Genome Res 2002; 12: 1466-1482.
16. Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999; 26: 355-365.
17. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002; 16: 1176-1181.
18. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
19. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53-59.
20. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000, 95: 62-66.
21. Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001; 112: 916-926.
22. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998; 12: 1482-1489.
23. Degan M, Mazzocco FT, Di Francia R, Rossi FM, Pinto A, Gattei V. Normalizing complementary DNA by quantitative reverse transcriptase-polymerase chain reaction of beta2-microgloiin: molecular monitoring of minimal residual disease in acute promyelocytic leukemia. Diagn Mol Pathol 2000; 9: 98-109.
24. Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients 'late', 18 months or more after transplantation. Blood 2001; 98: 1701-1707.
25. Krauter J, Hoellge W, Wattjes MP, Nagel S, Heidenreich O, Bunjes D et al. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes Chromosomes Cancer 2001; 30: 342-348.
26. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14: 324-328.
27. Bailerini P, Landman Parker J, Laurendeau I, Olivi M, Vidaud M, Adam M et al. Quantitative analysis of TEL/AML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 1526-1528.
28. Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001; 15: 1072-1080.
29. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grirnwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 2003; (in press).
30. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimJI residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
31. Dirnhofer S, Berger C, Untergasser G, Geley S, Berger P. Human beta-actin retropseudogenes interfere with RT-PCR. Trends Genet 1995; 11: 380-381.
32. Arcari P, Martinelli R, Salvatore F. Human glyceraldehyde-3-phosphate dehydrogenase pseudogenes: molecular evolution and a possible mechanism for amplification. Biochem Genet 1989; 27: 439-450.
33. Kollia P, Stavroyianni N, Stamatopoulos K, Zoi K, Viniou N, Mantzourani M et al. Molecular analysis of transferrin receptor mRNA expression in acute myeloid leukaemia. Br J Haematol 2001; 115: 19-24.
34. Sposi NM, Cianetti L, Tritarelli E, Pelosi E, Militi S, Barberi T et al. Mechanisms of differential transferrin receptor expression in normal hematopoiesis. Eur J Biochem 2000; 267: 6762-6774.
35. Willenbrink W, Halaschek J, Schuffenhauer S, Kunz J, Steinkasserer A. Cyclophilin A, the major intracellular receptor for the immunosuppressant cyclosporin A, maps to chromosome 7p112-p13: four pseudogenes map to chromosomes 3, 10, 14, and 18 Genomics 1995; 28: 101-104.
36. Kidd V, Lion T. Debate round-table. Appropriate controls for RT-PCR. Leukemia 1997; 11: 871-881.
37. Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL, Hokland P. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with ST1571 measured by quantitative real-time polymerase chain reaction. Eur J Haematol 2001; 67: 302-308.
38. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman IM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
39. Lyon MF. X-chromosome inactivation and human genetic disease. Acta Paediatr Suppl 2002; 91: 107-112,
40. Lupberger J, Kreuzer KA, Baskaynak G, Peters UR, le Coutre P, Schmidt CA. Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol Cell Probes 2002; 16: 25-30.
41. Hamalainen HK, Tubman JC, Vikman S, Kyrola T, Ylikoski F, Warrington JA et al. Identification and validation of endogenous reference genes for expression profiling of T helper cell differentia. tion by quantitative real-time RT-PCR. Anal Biochem 2001; 299: 63-70.